Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of NFL-101 to Reduce Reinforcing Properties of Cigarettes
2022-002492-11Phase 2Completed
- Sponsor
- NFL Biosciences
- Start
- Jul 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nicotine dependence comparing NFL-101 with Placebo (2 arms). Primary endpoint: Primary mCEQ Smoking Satisfaction at D4. Started Jul 2022; status: completed.
02
Drugs
nfl-101
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on 2022-002492-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002492-11.